Safety and efficacy of supported, at-home, sublingual ketamine telehealth for depression: New findings from a large, open-label effectiveness trial.
Abstract
Our aim for the present study is to replicate previous analysis of supported, at-home, sublingual ketamine telehealth for depression in a substantially larger patient sample (n ~ 10,000) obtained through ongoing data collection with the same telemedicine platform and to further clarify the safety and efficacy of this therapeutic modality. Building on the previous findings, we will investigate new data including the average ketamine dose prescribed to patients, the qualifications of ketamine prescribers (e.g., degree types), and characteristics/outcomes for patients who opted for a second round of ketamine treatment. We will also utilize longitudinal trajectory and network analyses to further describe the overall study population and to explore predictors of treatment outcome, which could inform personalized clinical decision-making with ketamine.
Topics & conditions
Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.
Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.